New York State Medicaid Drug Utilization Board Meeting Agenda

The Drug Utilization Review (DUR) Board will meet October 19, 2017, from 9:00 a.m. to 4:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

Agenda Items

A. Preferred Drug Program (PDP) Reviews

The DUR Board will review therapeutic classes listed below, as they pertain to the PDP.

➢ The DUR Board will review clinical and financial information, to recommend preferred and non-preferred drugs.

➢ For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information.

   New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

➢ Those wishing to submit clinical information must do so in an electronic format by October 4, 2017 or the DUR Board may not have sufficient time to review the information.

1. Hepatitis B Agents
   (initial Review)
   adefovir dipivoxil, Baraclude (entecavir), entecavir, Epivir-HBV (lamivudine), Hepsera (adefovir), lamivudine, Tyzeka (telbivudine), Vemlidy (tenofovir alafenamide)

2. Hepatitis C - Direct Acting Antivirals (DAA)*
   (previous review date: September 15, 2016)
   Copegus (ribavirin), Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir),Moderiba (ribavirin), Olysio (simeprevir), Rebetol (ribavirin), Ribaspere Ribapak (ribavirin), Ribaphere (ribavirin), ribavirin, Sovaldi (sofosbuvir), Technivie (ombitasvir/paritaprevir/ritonavir), Viekira Pak/Viekira XR (ombitasvir/paritaprevir/ritonavir/dasabuvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Zepatier (elbasvir and grazoprevir)

   * Includes a review of drug utilization in the fee-for-service (FFS) and managed care programs and current clinical criteria in the FFS program.
3. **Glucocorticoids-oral**  
   (previous review date: June 27, 2013)  
budesonide EC, Cortef (hydrocortisone), cortisone, dexamethasone, Dexamethasone Intensol (dexamethasone), Dexpak (dexamethasone), Emflaza (deflazacort), Entocort EC (budesonide), hydrocortisone, Medrol (methylprednisolone), methylprednisolone, Millipred (prednisolone), Orapred ODT (prednisolone sodium phosphate), prednisolone, prednisone, Prednisone Intensol (prednisone), Rayos (prednisone), Uceris (budesonide), Veripred (prednisolone)

4. **Anti-Emetics**  
   (previous review date: June 16, 2012)  
Akynzeo (netupitant/palonosetron), Anzemet (dolasetron), Diclegis (doxylamine succinate/pyridoxine HCl), Emend (aprepitant), granisetron, ondansetron, Sancuso (granisetron patch), Varubi (rolapitant), Zofran (ondansetron), Zuplenz (ondansetron)

**B. Drug Utilization Reviews**

The DUR Board will review the following pharmacotherapies and recommend clinical criteria and/or interventions to ensure appropriate utilization:

1. Sedative Hypnotics - evaluation of therapy duration
2. Codeine/tramadol - evaluation of safety
3. Methadone - evaluation in pain management
4. Management of Atopic Dematitis
5. Management of Rosacea

**C. Retrospective DUR Programmatic Updates**

The DUR Board will be provided updates on the following topics:

1. COPD and Influenza Vaccine Project
2. Fluoroquinolones: FDA Warnings Project

**Agenda Timeline** (subject to change based on meeting proceedings)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:15</td>
<td>Welcome &amp; Introductions</td>
</tr>
<tr>
<td>9:15 - 10:15</td>
<td>Public Comment Period</td>
</tr>
<tr>
<td>10:15 – 11:45</td>
<td>PDP Clinical Reviews</td>
</tr>
<tr>
<td>11:45 - 12:30</td>
<td>Drug Utilization Reviews</td>
</tr>
<tr>
<td>12:30 - 1:45</td>
<td>Lunch/Executive Session/Financial Review</td>
</tr>
<tr>
<td>Time</td>
<td>Agenda Item</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>1:45 – 2:00</td>
<td>PDP Recommendations</td>
</tr>
<tr>
<td>2:00 - 3:00</td>
<td>Drug Utilization Reviews (continued)</td>
</tr>
<tr>
<td>3:00 - 3:30</td>
<td>Retrospective DUR Programmatic Updates</td>
</tr>
<tr>
<td>3:30 - 4:00</td>
<td>Final Comments and Adjournment</td>
</tr>
</tbody>
</table>

Interested parties must notify the Department of Health (DoH) by October 11, 2017 of their request to address the DUR Board during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov. (please reference DUR Board Speaker Request).

Public comments are limited to the agenda items listed above. In addition, public comments for therapeutic classes currently subject to the PDP are limited to new clinical information since the previous review. Comments must be brief (2 minutes) and the total comment period will not exceed sixty (60) minutes. DoH reserves the right to limit the number of interested parties providing public comment in order to meet timelines and accomplish meeting objectives.

All clinical information must be received in an electronic format by October 4, 2017, or the DUR Board may not have ample time to review the information. For the therapeutic classes currently subject to the PDP, submitted clinical information must be new since the previous review of the therapeutic class. Any written statements, must be received in an electronic format by October 11, 2017. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Any information regarding the DUR Board meeting must be sent to the DoH to ensure distribution to all DUR Board members. Interested parties should not contact or send any information directly to DUR Board members.